We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunoassays Correlated With Systemic Lupus Erythematosus Activity

By LabMedica International staff writers
Posted on 15 Sep 2011
Three immunoassays have been compared for their ability to monitor the progression of the disease systemic lupus erythematosus (SLE). More...


Quantitative measurement of anti-double stranded DNA (dsDNA) antibodies plays a central role in monitoring the autoimmune connective tissue disease SLE, and results are incorporated into the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K).

Scientists at the University Health Network (Toronto, ON, Canada) analyzed 105 patient samples for anti-dsDNA antibodies and results were interpreted as positive or negative according to manufacturer cut-off limits. A multiplex anti-dsDNA immunoassay and an enzyme anti-dsDNA immunoassay assay were investigated as potential alternatives to the Farr-radioisotope immunoassay (RIA).

The BioPlex 2200 multiplex immunoassay (BPx, Bio-Rad Laboratories; Hercules, CA, USA) and the Quanta Lite “Farrzyme” enzyme immunoassay (EIA, INOVA Diagnostics; San Diego, CA, USA) met the stated analytical performance claims, but EIA maintained the widest measurable range. Only 33% SLE patients tested positive on BPx and only 31% with the EIA as compared with the 48% for Farr-RIA. Correlation between Farr-RIA and BPx assay results was poor with 62% positive agreement and 85% negative agreement. There was also poor correlation between the Farr-RIA and EIA with 56% lower positive agreement, but a better negative agreement of 91%.

The mean SLEDAI-2 K scores differed significantly between positive and negative result groups for Farr-RIA and BPx, but not for EIA and the authors suggest suggests it may be appropriate to lower the EIA cut-off point. The authors concluded that the optimal alternative for the Farr-RIA assay remains equivocal. There are ongoing analyses of clinical follow-up and anti-dsDNA measurements, which will aid in determining the most appropriate alternative. The article was published on August 15, 2011, in the journal Clinical Biochemistry.

Related Links:
University Health Network
Bio-Rad Laboratories
INOVA Diagnostics




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.